Acrivon Therapeutics, Inc.

Company overview

• Clinical-stage biopharmaceutical company focused on discovering and developing precision medicines.
• Core platforms: Generative Phosphoproteomics AP3 platform and OncoSignature companion diagnostics.
• Strategy: Use proteomics-based, drug-tailored biomarker tests to identify patient responders and optimize drug development, with the goal of expanding precision oncology beyond genetically defined populations.

AP3 platform and OncoSignature diagnostics

• AP3 platform: Combines high-resolution MS-based phosphoproteomics with automated tumor imaging biomarker workflows (AP3 Interactome, AP3 Kinase Substrate Relationship Predictor, AP3 Data Portal, AP3 Chatbot) to quantify compound-specific pathway activity inside intact cells.
• Primary outputs and applications:
  • Drug target engagement and pharmacodynamic biomarkers
  • Indication finding and biomarker-based patient selection
  • Drug combination identification and resistance mechanism mapping
  • Support for rational drug design, including structure-guided optimization and co-crystallography
• OncoSignature tests: Drug-tailored, automated quantitative proteomic tissue imaging tests used as companion diagnostics to select patients predicted to benefit from a drug candidate.
• CLIA lab: Internal CLIA-certified laboratory established in Watertown, MA (certified February 18, 2026) to perform in-house OncoSignature testing and clinical assays.
• IP position: Patent families cover OncoSignature tests and related methods; in-house CLIA testing reduces dependency on external partners.

Lead clinical programs and pipeline

• ACR-368 (prexasertib)
  • Selective CHK1/2 inhibitor.
  • Phase 2b lead program operating under an FDA master protocol with three registrational-intent arms using OncoSignature for patient selection.
  • ACR-368 OncoSignature predicts treatment benefit; Arm 1 enrolls OncoSignature-positive endometrial cancer (EC) subjects; additional arms explore serous EC populations with and without ULDG sensitization or monotherapy.
  • Prior exposure: More than 400 patients dosed across Lilly-sponsored and other trials at the RP2D, with observed deep responses and favorable tolerability informing current design.
  • Interim EC and serous EC data informed expansion to serous EC arms and ULDG sensitization.
• ACR-2316
  • Internally discovered dual WEE1/PKMYT1 inhibitor designed for enhanced single-agent activity.
  • Phase 1 dose-escalation trial; initial data reported late 2025/early 2026 showing tolerability and early activity signals in AP3-selected solid tumors, including EC, SCLC, and sqNSCLC.
  • Development incorporates AP3-guided SAR, co-crystallography, and planned OncoSignature-based target engagement and dose optimization.
• ACR-6840
  • Preclinical CDK11 inhibitor with IND-enabling studies planned for 4Q 2026.
  • Preclinical data show pro-apoptotic activity, MCL1 downregulation, and synergy with BCL2 inhibitors.
• Platform-enabled discovery: AP3-based indication finding and analyses used to identify tumor types with predicted sensitivity to ongoing programs.
• Business development: Company pursues in-licensing and co-development opportunities to expand the pipeline.

Licensing, collaborations, and corporate transactions

• Lilly license for ACR-368: Exclusive, royalty-bearing sublicensable license with milestone payments up to $168.0 million (only $5.0 million due before NDA), tiered royalties on net sales, and a right of first negotiation for reacquisition; Lilly fully released the ROFN in July 2025.
• Akoya collaboration: Agreement to co-develop, validate, and commercialize ACR-368 OncoSignature (June 2022). Terminated February 25, 2026, with a transition plan to bring testing in-house via the CLIA lab. No financial settlements were paid by either party as part of the termination.
• Blume-Jensen license (April 2018): Broad, exclusive, perpetual license for biomarker discovery and OncoSignature-related technology.

Intellectual property

• Patent coverage: In-licensed and company-owned patent families cover ACR-368, AP3 platform methods, and OncoSignature tests across the US and international jurisdictions, with standard patent terms and potential extensions.
• Trademarks: OncoSignature is registered in the US and other jurisdictions; Acrivon, AP3, and related marks are being filed.
• Trade secrets: Core platform know-how is protected as trade secrets in addition to patent protection.

Corporate operations and facilities

• Headquarters: Watertown, Massachusetts (principal executive office).
• Additional presence: Nordic development operations in Lund, Sweden.
• Facilities:
  • 13,711 sq ft of office/lab space in Watertown.
  • Lund facilities with leases expiring 2026 and an adjacent space lease effective September 2024 for a three-year term with automatic renewal options.
• Manufacturing and supply: Reliance on contract manufacturers (CMOs) for drug substance and product; multiple CMOs engaged to support ongoing trials.

People and organization

• Headcount: 76 employees (74 full-time, 2 part-time) as of December 31, 2025.
• Qualifications: Approximately 44 employees hold Ph.D. or M.D. degrees; about 64 employees work in research and development.
• Focus areas: Oncology signaling, proteomics, and precision medicine; leadership includes founders with deep expertise in phosphoproteomics, oncology drug discovery, and clinical development.

Financial snapshot (as of December 31, 2025)

• Revenue: None.
• Net losses: $77.9 million in 2025; $80.6 million in 2024.
• Accumulated deficit: $274.9 million.
• Cash and investments: $118.6 million.
• Runway: Existing resources expected to fund operations into the second quarter of 2027.
• Funding needs: Additional funding will be required to continue operations and advance the pipeline; no committed external source of funds disclosed in the filing.
• Revenue model: Future revenue is expected to come from licensing, collaborations, or product sales contingent on approvals.

Market and strategic positioning

• Therapeutic focus: Oncology, with emphasis on DNA damage response pathways, cell cycle regulation, and signaling pathways where genetics-based selection has been limited.
• Competitive landscape: Multiple CHK, WEE1, and PKMYT1 programs exist across the industry; AP3 is a proteomics-based precision medicine approach intended to expand patient populations beyond genetics-defined cancers.
• Clinical strategy: Pursue accelerated pathways where applicable, combine with other therapies (for example, anti-PD-1), and validate companion diagnostics alongside development.